PURPOSE: To study changes of the apparent diffusion coefficient (ADC) measured by magnetic resonance imaging (MRI) in patients with primary rectal carcinoma during a course of combined chemoradiation. PATIENTS AND METHODS: Diffusion-weighted echo-planar imaging at 1.5 T was performed in patients (n = 8) with primary rectal carcinoma (cT3) undergoing preoperative chemoradiation. Mean tumor ADC values and ADC histograms were determined and compared weekly during the course of therapy. Surgical resection of the tumors enabled a correlation of ADC values with the pathologic classification. RESULTS: In four patients tumor T-downstaging (ypT0-2) was observed, and in four patients no downstaging (ypT3) was seen. In all patients, ADC values were higher before onset of chemoradiation therapy compared to the end of chemoradiation. Separating the patients into two groups, a significant increase in ADC value during week 1 of therapy, followed by a steady decrease, was found for the therapy-responder group. In the nonresponder group, no initial increase of ADC values was observed. After the 1st week of therapy, ADC values were significantly lower in the nonresponder group during the remaining duration of therapy. CONCLUSION: With these preliminary results it could be shown that MR diffusion imaging is able to detect individual changes of tumor ADC values during the course of combined chemoradiation reflecting biological changes within the tumor tissue. Further studies will be necessary to prove the possible value of totally noninvasive ADC imaging on predicting therapy outcome.
PURPOSE: To study changes of the apparent diffusion coefficient (ADC) measured by magnetic resonance imaging (MRI) in patients with primary rectal carcinoma during a course of combined chemoradiation. PATIENTS AND METHODS: Diffusion-weighted echo-planar imaging at 1.5 T was performed in patients (n = 8) with primary rectal carcinoma (cT3) undergoing preoperative chemoradiation. Mean tumor ADC values and ADC histograms were determined and compared weekly during the course of therapy. Surgical resection of the tumors enabled a correlation of ADC values with the pathologic classification. RESULTS: In four patientstumor T-downstaging (ypT0-2) was observed, and in four patients no downstaging (ypT3) was seen. In all patients, ADC values were higher before onset of chemoradiation therapy compared to the end of chemoradiation. Separating the patients into two groups, a significant increase in ADC value during week 1 of therapy, followed by a steady decrease, was found for the therapy-responder group. In the nonresponder group, no initial increase of ADC values was observed. After the 1st week of therapy, ADC values were significantly lower in the nonresponder group during the remaining duration of therapy. CONCLUSION: With these preliminary results it could be shown that MR diffusion imaging is able to detect individual changes of tumor ADC values during the course of combined chemoradiation reflecting biological changes within the tumor tissue. Further studies will be necessary to prove the possible value of totally noninvasive ADC imaging on predicting therapy outcome.
Authors: Craig J Galbán; Stefanie Galbán; Marcian E Van Dort; Gary D Luker; Mahaveer S Bhojani; Alnawaz Rehemtulla; Brian D Ross Journal: Prog Mol Biol Transl Sci Date: 2010 Impact factor: 3.622
Authors: Bradford A Moffat; Thomas L Chenevert; Charles R Meyer; Paul E McKeever; Daniel E Hall; Benjamin A Hoff; Timothy D Johnson; Alnawaz Rehemtulla; Brian D Ross Journal: Neoplasia Date: 2006-04 Impact factor: 5.715
Authors: Renu M Stephen; Abhinav K Jha; Denise J Roe; Theodore P Trouard; Jean-Philippe Galons; Matthew A Kupinski; Georgette Frey; Haiyan Cui; Scott Squire; Mark D Pagel; Jeffrey J Rodriguez; Robert J Gillies; Alison T Stopeck Journal: Magn Reson Imaging Date: 2015-08-15 Impact factor: 2.546
Authors: Craig J Galbán; Suresh K Mukherji; Thomas L Chenevert; Charles R Meyer; Daniel A Hamstra; Peyton H Bland; Timothy D Johnson; Bradford A Moffat; Alnawaz Rehemtulla; Avraham Eisbruch; Brian D Ross Journal: Transl Oncol Date: 2009-08-18 Impact factor: 4.243